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Chemotherapy employs chemical substances to interfere 
with the growth of cancer cells, and is a major treatment 
strategy in human cancer including acute myeloid leukemia 
(AML). Although they often effectively kill fast-dividing 
tumor cells, chemotherapeutic drugs also profoundly affect 
mutation spectrum of the tumor genome. Each chemothera-
peutic drug has a working concentration within an appropri-
ate range. Concentrations beyond this range will increase 
drug toxicity without adding clinical benefit, while concen-
trations below the range will result in an insufficient drug 
effect. The conventional strategy in oncology is to give a 
patient drugs at the maximum tolerated dose (MTD) in or-
der to kill as many tumor cells as possible. However, this 
inevitably causes a high rate of toxicity to normal tissue, as 
well as resulting in new mutations and genome instability 
which can lead to drug resistance and relapse. The priming 
induction regimen of HAG (low dose of cytarabine (Ara-C) 
and Homoharringtonine (HHT) with granulocyte colo-
ny-stimulating factor (G-CSF) priming), has proven to be 
effective in subgroup of AML patients in small scale clini-
cal studies. It is of great medical significance to explore 
whether low dose chemotherapy can reduce the side effect 
of chemotherapeutic drugs while maintaining the therapeu-
tic benefits, and whether such alternative therapeutic strat-
egy is advantageous compared to conventional intensive 
treatment regarding the development of drug resistance by 
affecting leukemic genome mutation load and clonal evolu-
tion in subgroup of AMLs.  
1  Clonal evolution and drug resistance after 
conventional chemotherapy in AML 
Despite the improvement in conventional intensive chemo-
therapy and stem cell transplantation, the overall 5-year 
survival of AML patients is only 40%–45% in young pa-
tients and less than 10% in the elderly patients. The majori-
ty of patients relapse with resistance to chemotherapy, and 
the cancer rapidly progresses. These tumors have undergone 
clonal evolution at the cytogenetic level, which is caused by 
a potent selection pressure from the chemotherapy [1].  
Although intensive chemotherapy is designed to eradi-
cate all tumor clones in a patient, recent studies show that it 
not only fails to kill the founding clone but also increases 
the risk of relapse by directly inducing new mutations that 
contribute to cancer evolution. By sequencing the whole 
genomes of 8 AML patients, Ding et al. [2] reveal two ma-
jor clonal evolution patterns at relapse after chemotherapy: 
either the founding clone in the primary tumor gained muta-
tions and evolved into a relapse clone or a subclone of the 
founding clone survived the initial therapy, gained addition-
al mutations and expanded at relapse. Moreover, it has been 
proposed that relapse-specific drug resistance mutations are 
likely to have been present in small populations of the 
founding clones, and intensive chemotherapy, which kills 
the maximum numbers of those founding clones, removes 
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the inhibitory effect on the small clones and eventually 
promotes more rapid growth of the resistant populations [3]. 
With such a potential threat of conventional chemothera-
pies, there is a critical need to adopt a new therapeutic con-
cept of chemotherapy in cancer treatment. 
2  Priming induction regimen of CAG or HAG 
chemotherapy in treating AML 
Conventional chemotherapy can achieve complete remis-
sion (CR) in 60%–80% of de novo AML patients. However, 
it also has limited efficacy in the remaining 20%–40% of de 
novo AML patients, especially in high-risk AML patients 
including elderly and relapsed/refractory (R/R) patients. As 
a result of drug resistance, poor performance status (PS), 
multiple organ dysfunction and high treatment-related tox-
icities, conventional chemotherapy is associated with a high 
early death (ED) rate. In an attempt to achieve reduced tox-
icity, better tolerance and improved life quality, a priming 
induction regimen, CAG (lower dose of Ara-C (1/10 dosage 
of conventional therapy) and aclarubicin (ACR) with 
G-CSF priming), was first proposed in 1995 by a Japanese 
group [4]. ACR is an anthracycline drug with an adverse 
effect of cardiotoxicity, and Ara-C is an antimetabolism 
agent targeting pyrimidine synthesis. As a sensitizer of S 
phase-specific cytotoxicity drugs, G-CSF can stimulate 
resting G0 phase cells into the G1 phase and mobilize the 
bone marrow leukemia cells to the peripheral blood. Fol-
lowing the priming of G-CSF, a combination of ACR with 
Ara-C is presumed to eliminate the leukemia cells with a 
higher efficiency [5]. In China, HHT, an alkaloid isolated 
from the Cephalotaxus plant, was used to replace ACR be-
cause HHT is less expensive and has a low risk of cardio-
toxicity. Therefore, the CAG regimen is referred to as 
HAG when HTT is used in place of ACR. Although an in-
creasing number of studies involve CAG and HAG regi- 
mens to treat AML, MDS and even ALL, priming induction 
regimens are still mainly used in elderly, R/R and secondary 
AML patients as a second line treatment exclusively in 
China and Japan.  
To systematically evaluate the efficacy of the CAG/HAG 
regimen in AML patients, we searched several databases, 
including PubMed and Web of Science, as well as the 
American Society of Hematology (ASH) and American 
Society of Clinical Oncology (ASCO) annual meeting ab-
stracts between 2009 and 2015 for clinical studies. Preclin-
ical trials, case reports and reviews were not included. Ten 
studies with a total of 416 patients were found (Table 1). 
Seven studies involving 250 AML patients used CAG and 
achieved a highly variable CR rates (21.2% to 63.5%). 166 
AML patients from four of the studies were under HAG 
treatment, and the CR rates ranged from 46.7% to 61.5%. 
The overall CR rates calculated with a random effect model 
in the AML patients were 47.2% (95% confidence interval 
(CI), 35.2%–59.2%) and 57.0% (95%CI, 50.3%–63.7%) for 
CAG or HAG, respectively. CAG, HAG and conventional 
standard regimens had similar CR rates in these studies 
(Fisher test P＞ 0.05). Additionally, CAG and HAG 
achieved similar CR rates in either 136 de novo or 280 R/R 
AMLs (49.0% versus 46.5%, 60.7% versus 56.0%, Fisher 
test P＞0.05). More recently, Li et al. [6] reported in Onco-
target that CAG in combination with decitabine achieved a 
CR rate of 82.4% in de novo elderly AML patients. 
The toxicity of the CAG/HAG regimen in all of the re-
ports was generally mild. Early death was reported in 13 out 
of 388 patients (3.4%), and no patient suffered from cardio-
toxicity. Most of the deaths were caused by severe infec-
tion, respiratory failure and cerebral vascular accident, 
which were significantly lower than the outcomes observed 
when conventional induction therapy was used. These data 
indicated that the CAG/HAG regimen is safe and effective 
as a promising induction therapy in AML, for both de novo 
and R/R patients. However, the overall survival (OS), pro-
Table 1  Efficacy, cardiotoxicity and early death rate of CAG and HAG in AMLa) 
 
Author Year Patients No. Median 
age(y)(range)
ACR/HHT dosage Subtype CR No. CR % OS (m)(range) CT No. ED No.
CAG 
regimen 
Su et al. 2009 33 60(28–77) 10 mg×8 d RR 14 42.4 NA 0 0 
Wei et al. 2012 23 41(14–60) 8–10 mg m2×8 d RR 13 56.5 NA 0 0 
Liu et al. 2014 37 46(15–76) 5–7 mg m2×14 d RR 23 62.2 6(2–36) 0 0 
Wang et al. 2014 33 2(15–66) 20 mg×4 d RR 7 21.2 NA 0 0 
Zheng et al. 2012 28 68(60–89) 20 mg ×3 or 4 d de novo 12 42.9 10.5(0.6–64.3) 0 NA 
Zhu et al. 2013 44 45(16–62) 10 mg×8 d RR 28 63.5 NA 0 0 
Jin et al. 2015 52 68(60–80) 6–7 mg m2×14 d de novo 29 55.5 12.1(0.65–11.7) 0 2 
HAG  
regimen 
Su et al. 2009 30 68(17–88) 1 mg×14 d RR 14 46.7 NA 0 0 
Wu et al. 2011 13 71(60–88) 1 mg×14 d RR 8 61.5 NA 0 0 
Gu et al. 2011 67 50(15–77) 1.5 mg m2×14 d RR 35 52.2 12.5(0.5–37) 0 7 
Chen et al. 2015 56 72(60–80) 1.5 mg m2×14 d de novo 34 60.7 12(8.6–15.4) 0 4 
a) AML: acute myeloid leukemia; CR: complete remission; OS: overall survival; CT: cardiotoxicity; ED: early death; NA: not available; CAG: Ara-C, 
ACR and G-CSF; HAG: HHT, Ara-C and G-CSF. 
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gression free survival (PFS) and relapse rate were rarely 
reported in these studies. Further large-scale prospective, 
randomized controlled investigations should be performed 
to systematically evaluate the long-term efficacy of the 
CAG/HAG regimen. 
3  Priming induction regimen of chemotherapy 
and clonal evolution in AML 
Over the last six years, several groups applied mathematical 
models to define the patterns of tumor clonal evolution un-
der the treatment of different chemotherapeutic drug dos-
age. They proposed that, there are pre-existing small popu-
lations of chemotherapy-resistant subclones in cancer pa-
tients and that the presence of the founding clones can sup-
press the expansion of the resistant clones. By killing most 
of the cells in a founding clone, conventional chemotherapy 
also removes this inhibitory effect and eventually promotes 
the rapid growth of the resistant populations. Alternatively, 
if a therapy allows the founding clone to survive at a toler-
ated tumor load, the founding clone will, in turn, suppress 
the growth of the resistant population [3,7,8]. Their models 
provide a novel therapeutic concept and support the validity 
of low dose chemotherapy. 
By imparting a reduced selection pressure on the leuke-
mic genome and clonal structure, the priming induction 
regimen of HAG may give rise to a more beneficial clinical 
outcome in the long run. There is increasing evidence to 
show that a low(er) dose instead of an MTD therapy can 
maintain a minimum tumor burden, which in turn, may re-
strain the proliferation of the most resistant clones. A recent 
study indicated that the priming induction regimen might 
also help to prevent the quiescent cancer stem cells (CSC) 
to become activated and cause tumor progression and 
post-treatment cancer relapse [9]. Moreover, low dose 
chemotherapy is presumed to have less impairment on the 
bone marrow microenvironment and immune system. To-
gether, these beneficial effects may lead to a better recovery 
of hematopoiesis after chemotherapy, as well as retain a 
sensitive response to the same regimen or similar chemo-
therapy upon relapse (Figure 1).  
4  Summary and perspectives 
Collectively, multiple small-scale clinical studies support 
the priming induction regimen of low doses administration 
as a promising alternative to conventional intensive strategy 
in AML induction therapy for high risk patients. The 
short-term efficacy, reduced side effect and lower costs of 
the priming induction regimen are evident, large-scale in-
vestigations are still needed to evaluate OS, PFS and relapse 
rate. Although it is not a focus of this review, alterna-  
 
Figure 1  The distinct clonal evolution patterns under the selection of 
conventional or low-dose chemotherapy. A, High dose chemotherapeutic 
drugs eradicate most cells from the founding clone, and leave the 
pre-existing small populations of drug-resistant subclones to expand upon 
relapse. B, A proposed model: low drug dosage kills tumor cells without 
impacting the clonal structure, relapsed tumors are still sensitive to the 
same or similar chemotherapy regimens. 
tive priming agents are also used in the clinic. For example, 
priming with dichloroacetate (DCA) significantly potenti-
ated the cytotoxicity of arsenic trioxide (ATO) in AML 
cells in a synergistic manner. The combination decreased 
the mitochondrial membrane potential as well as expression 
of Mcl-1 and GPx in primary AML cells more than either 
drug alone [10]. Intriguing, mathematical modeling and 
recent genomic studies suggest a potential inhibitory effect 
of low dose chemotherapy on the evolution of drug-resistant 
clones. Future studies are warranted to determine if the dis-
tinct evolutionary course exerted by low dose chemotherapy 
may lead to improved clinical outcomes by reducing relapse 
and drug resistance, at least in subgroup of AML patients. 
Therefore, the decision can be made to choose “the right 
dose” in precision medicine. 
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